期刊
CELL CYCLE
卷 10, 期 15, 页码 2497-2503出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.10.15.16776
关键词
RB; p16; CDKN2a; E2F; CDK; cyclin; therapy; radiation
类别
资金
- NCI NIH HHS [R01 CA099996] Funding Source: Medline
The CDKN2A gene is a tumor suppressor that encodes the CDK4/6 inhibitor p16(ink4a). Loss of this tumor suppressor contributes to the bypass of critical senescent signals and is associated with progression to malignant disease. However, the high-level expression of p16(ink4a) in tumors is associated with aggressive subtypes of disease, and in certain clinical settings elevated p16(ink4a) expression is an important determinant for disease prognosis and therapeutic response. These seemingly contradictory facets of p16(ink4a) expression have lead to confusion related to the meaning of this tumor suppression in tumor pathobiology. As reviewed here, the alternative expression of p16(ink4a) represents an ideal marker for considering RB-pathway function, tumor heterogeneity and novel means for directing therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据